

# Martin H Voss

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7444844/publications.pdf>

Version: 2024-02-01

30  
papers

2,145  
citations

430874

18  
h-index

552781

26  
g-index

31  
all docs

31  
docs citations

31  
times ranked

3792  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. <i>Science</i> , 2018, 359, 801-806.	12.6	898
2	Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 1349-1357.	9.4	226
3	Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial. <i>Cancer Discovery</i> , 2019, 9, 510-525.	9.4	169
4	Towards individualized therapy for metastatic renal cell carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 621-633.	27.6	148
5	A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations. <i>Clinical Cancer Research</i> , 2019, 25, 2699-2707.	7.0	98
6	Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates. <i>Journal of Clinical Oncology</i> , 2022, 40, 2333-2341.	1.6	72
7	Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. <i>British Journal of Cancer</i> , 2020, 123, 1590-1598.	6.4	57
8	A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response. <i>Nature Communications</i> , 2020, 11, 4168.	12.8	46
9	Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 2910-2919.	7.0	45
10	DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy. , 2020, 8, e000230.		37
11	PTEN Expression, Not Mutation Status in <i>TSC1</i> , <i>TSC2</i> , or <i>mTOR</i> , Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial. <i>Clinical Cancer Research</i> , 2019, 25, 506-514.	7.0	31
12	Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression. <i>Clinical Cancer Research</i> , 2020, 26, 3629-3640.	7.0	30
13	Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. , 2021, 9, e001884.		27
14	A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5202-5211.	7.0	26
15	Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations. <i>Clinical Cancer Research</i> , 2021, 27, 3845-3853.	7.0	25
16	Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6687-6695.	7.0	25
17	A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 4994-5003.	7.0	24
18	Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. <i>Cancer</i> , 2020, 126, 5247-5255.	4.1	22

#	ARTICLE	IF	CITATIONS
19	Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial. <i>Clinical Cancer Research</i> , 2022, 28, 1540-1548.	7.0	21
20	The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. <i>European Urology Oncology</i> , 2020, 3, 47-56.	5.4	20
21	High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab. <i>Molecular Cancer Research</i> , 2021, 19, 1510-1521.	3.4	20
22	A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma. <i>Cancer</i> , 2019, 125, 2400-2408.	4.1	18
23	Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5595-5606.	7.0	12
24	Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma. <i>Cancer</i> , 2021, 127, 3946-3956.	4.1	12
25	Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial. <i>Clinical Cancer Research</i> , 2022, 28, 738-747.	7.0	11
26	Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2021, 124, 237-246.	6.4	10
27	A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 3032-3041.	7.0	7
28	In silico modeling of combination systemic therapy for advanced renal cell carcinoma. , 2021, 9, e004059.		5
29	Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e178-e183.	1.9	2
30	Up-front Nivolumab With or Without Salvage Ipilimumab Across International Metastatic Database Consortium Risk Groups in Metastatic Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 0, , .	1.6	0